These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20160047)

  • 1. Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
    Vourvahis M; Banerjee S; LaBadie R; Gore D; Mayer H
    Antimicrob Agents Chemother; 2010 May; 54(5):2209-11. PubMed ID: 20160047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
    Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
    Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
    Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
    J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.
    Vourvahis M; Langdon G; Layton G; Labadie RR; Choo HW; Ndongo MN; Davis J
    J Acquir Immune Defic Syndr; 2012 May; 60(1):24-32. PubMed ID: 22517413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
    Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
    Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients.
    Fätkenheuer G; Staszewski S; Plettenburg A; Hackman F; Layton G; McFadyen L; Davis J; Jenkins TM
    AIDS; 2009 Oct; 23(16):2115-22. PubMed ID: 19779321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.
    Snell P; Oo C; Dorr A; Barrett J
    Br J Clin Pharmacol; 2002 Oct; 54(4):372-7. PubMed ID: 12392584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics.
    Martin PD; Schneck DW; Dane AL; Warwick MJ
    Curr Med Res Opin; 2008 Apr; 24(4):1231-5. PubMed ID: 18355422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers.
    Krishna G; Kisicki JC; Olsen S; Grasela DM; Wang Z
    Pharmacotherapy; 2007 Jul; 27(7):963-9. PubMed ID: 17594201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of omeprazole or of an aluminium hydroxide/magnesium hydroxide antacid on the pharmacokinetics of lumiracoxib.
    Scott G; Vinluan Reynolds C; Milosavljev S; Langholff W; Shenouda M; Rordorf C
    Clin Pharmacokinet; 2004; 43(5):341-8. PubMed ID: 15080766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers.
    Grunder G; Zysset-Aschmann Y; Vollenweider F; Maier T; Krähenbühl S; Drewe J
    Antimicrob Agents Chemother; 2006 Jan; 50(1):68-72. PubMed ID: 16377669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.
    Lober S; Ziege S; Rau M; Schreiber G; Mignot A; Koeppe P; Lode H
    Antimicrob Agents Chemother; 1999 May; 43(5):1067-71. PubMed ID: 10223915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
    Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
    Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers.
    Jones LH; Allan G; Corbau R; Middleton DS; Mowbray CE; Newman SD; Phillips C; Webster R; Westby M
    Chem Biol Drug Des; 2011 May; 77(5):393-7. PubMed ID: 21352504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
    Davis J; Langdon G; Layton G; Chong CL; Ndongo MN; Vourvahis M
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1567-72. PubMed ID: 22527351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.